IMBRUVICA Drug Patent Profile

When do Imbruvica patents expire, and when can generic versions of Imbruvica launch?

Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. There are fifty-six patents protecting this drug and four Paragraph IV challenges.

This drug has four hundred and ninety patent family members in fifty countries.

The generic ingredient in IMBRUVICA is ibrutinib. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ibrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Imbruvica

Imbruvica was eligible for patent challenges on November 13, 2017.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are six tentative approvals for the generic drug (ibrutinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for IMBRUVICA

International Patents:	490
US Patents:	56
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	151
Patent Applications:	3,873
Drug Prices:	Drug price information for IMBRUVICA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMBRUVICA
What excipients (inactive ingredients) are in IMBRUVICA?	IMBRUVICA excipients list
DailyMed Link:	IMBRUVICA at DailyMed

See drug prices for IMBRUVICA

Recent Clinical Trials for IMBRUVICA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Peter MacCallum Cancer Centre, Australia	Phase 2
Oncternal Therapeutics, Inc	Phase 3
Academic and Community Cancer Research United	Phase 2

See all IMBRUVICA clinical trials

Pharmacology for IMBRUVICA

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for IMBRUVICA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMBRUVICA	Capsules	ibrutinib	70 mg	205552	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	280 mg and 420 mg	210563	1	2018-12-14
IMBRUVICA	Tablets	ibrutinib	560 mg	210563	1	2018-11-05
IMBRUVICA	Capsules	ibrutinib	140 mg	205552	8	2017-11-13

US Patents and Regulatory Information for IMBRUVICA

IMBRUVICA is protected by eighty-seven US patents and five FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes	10,751,342*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-004	Feb 16, 2018		DISCN	Yes	No	10,828,259*PED				Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-003	Feb 16, 2018		RX	Yes	Yes	8,999,999*PED				Y

EU/EMA Drug Approvals for IMBRUVICA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Imbruvica	ibrutinib	EMEA/H/C/003791IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.	Authorised	no	no	no	2014-10-21

International Patents for IMBRUVICA

When does loss-of-exclusivity occur for IMBRUVICA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Israel

Japan

Jordan

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Russian Federation

Singapore

South Africa

South Korea

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMBRUVICA around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2201840
Mexico	2021012478
Japan	6869400

Supplementary Protection Certificates for IMBRUVICA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2201840	C20150014 00145	Estonia		PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
2526934	PA2016034	Lithuania		PRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526
2201840	CR 2015 00021	Denmark		PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023

Market Dynamics and Financial Trajectory for Imbruvica

Last updated: February 20, 2026

What Is the Current Market Position of Imbruvica?

Imbruvica (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor developed by AbbVie and Janssen. Approved in 2013 for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM), it quickly established a leadership role in targeted oncology treatments. As of 2023, Imbruvica remains a top-selling lymphoma drug but faces increasing competition from newer agents.

Market share status (2023):

Indication	Market Share	Competing Agents	Market Share of Competitors
CLL	45%	Calquence (Acalabrutinib), Venclexta	20-25% (Venclexta), 15-20% (Calquence)
MCL	50%	Polivy (polatuzumab), Tecentriq	10-15% (Polivy), less in MCL
WM	55%	Rituxan, second-generation BTK inhibitors	20-25%

Imbruvica's strong presence is due to its early approval, extensive clinical data, and broad label approvals.

How Do Market Conditions Influence Imbruvica’s Revenue?

Multiple factors impact Imbruvica’s sales trajectory:

1. Market Penetration: The drug has achieved high penetration in first-line and relapsed settings across multiple indications, generating peak revenues in 2018 and 2019.

2. Pricing Strategy: As a high-cost targeted therapy, Imbruvica maintains premium pricing. In the U.S., wholesale acquisition costs (WAC) fluctuate around $14,000-$15,000 monthly per patient, with negotiated discounts reducing net revenue.

3. Patent Expiry and Biosimilar Threats:

   • Patent protection extends into late 2020s, with a key composition patent expiring in 2027 in the U.S.[1].
   • Biosimilars and generics are unlikely to compete directly due to the drug’s molecular complexity and patent protections, but price erosion remains a risk post-expiry.

4. Regulatory Developments:

   • FDA approvals for new indications bolster revenue streams (e.g., MCL in 2016, WM in 2015).
   • Ongoing trials exploring combination therapies could expand usage.

5. Competitive Landscape:

   • Second-generation BTK inhibitors (e.g., Acalabrutinib, Zanubrutinib) associated with reduced side effects are gaining market share.
   • Venclexta (venetoclax) is competitive in CLL and other hematologies.

6. Pipeline and New Indications:

   • Studies in autoimmune diseases and solid tumors are ongoing, which could diversify revenue sources.

What Are the Financial Trends for Imbruvica?

AbbVie and Janssen report combined revenues for Imbruvica as part of hematologic malignancy therapies. Data from 2022 indicates:

Year	Revenue (USD billions)	Change vs. Previous Year
2020	6.4	+12%
2021	6.7	+4.7%
2022	6.83	+1.8%

The growth rate slowed in 2022, reflecting increased competition and market saturation.

Projections (2023-2025):

• Revenue expected to plateau at approximately $6-6.5 billion annually.
• Post-2027, revenues will decline as patent protections expire and biosimilar entry begins, with estimates predicting a 40-50% decline over five years after patent expiry.

How Do Patent and Regulatory Timelines Shape Future Revenue?

Patent lifecycle:

Patent Type	Expiry Year	Description
Composition Patent	2027	Protects drug molecule
Method of Use (indications)	2025-2028	Broad coverage
Manufacturing Patent	2024	Certain formulations

Regulatory filings and label expansions up to 2024 may maintain or increase sales, but revenue erosion aligns with patent expirations.

What Is the Outlook for Future Market Share?

Sales growth will depend on:

• Approval of new indications (combination therapies, solid tumors).
• Competitive dynamics with second-generation BTK inhibitors.
• Pricing and payer access strategies.

Imbruvica’s market share is forecasted to decrease gradually from dominance to a niche player post-2028, unless new indications significantly expand its use.

Implications for Stakeholders

Investors should monitor patent expiration schedules and pipeline developments. Pharma companies can seek to extend lifecycle through combination approvals or novel formulations. Healthcare providers will weigh the benefits of Imbruvica against emerging, potentially safer or more effective options.

---

Key Takeaways

• Imbruvica has maintained a dominant position in hematologic oncology with peak revenues around $6.8 billion in 2022.
• Revenue growth has slowed amid increasing competition and approaching patent expiry.
• Patent protections extend into late 2020s; biosimilar entry is expected post-2027.
• Future sales hinge on new indications, combination therapies, and market penetration strategies.
• A decline in revenue of 40-50% is projected in the five years following patent expiration unless new uses or formulations are approved.

---

FAQs

1. When are Imbruvica’s patents expected to expire?
Composition patents expire around 2027 in the U.S., with some indication patents extending into 2028.

2. How does competition affect Imbruvica’s pricing?
Price erosion occurs as biosimilars and generics enter post-expiry, but high manufacturing complexity and patent protections delay this process.

3. What new indications might extend Imbruvica’s market life?
Ongoing trials in autoimmune diseases and solid tumors could broaden use, but regulatory approval is uncertain.

4. How will biosimilar entry impact revenue?
Entry post-2027 is likely to reduce Imbruvica’s market share, with estimates of 40-50% revenue decline over five years.

5. What strategic moves can AbbVie and Janssen take to sustain revenues?
Seeking new indications, expanding combination therapies, and optimizing payer access are primary strategies.

---

References

[1] U.S. Patent and Trademark Office. (2022). Patent expiration dates for Imbruvica.
[2] Evaluate Pharma. (2023). Oncology drug sales data.
[3] FDA databases. (2023). Approved indications and pipeline updates.